Abstract | INTRODUCTION:
Difluprednate ophthalmic emulsion 0.05% (Durezol™, Alcon, Fort Worth, Texas) is a topical difluorinated derivative of prednisolone with potent anti-inflammatory activity. Difluprednate 0.05% has a reported associated increase in intraocular pressure (IOP) in 3% of patients. Although the occurrence may be low, the possible elevation in IOP may be substantially higher than commonly encountered with other topical steroids. CASE REPORTS: CONCLUSION:
Difluprednate 0.05% is a new topical therapeutic option indicated for the treatment of inflammation and pain management associated with ocular surgery with an off-label potential for treatment of other anterior segment inflammatory conditions. However, clinicians need to be aware of the potential risk for significant and potentially rapid onset of IOP increase with this medication and manage patients accordingly.
|
Authors | Kelly Meehan, Lori Vollmer, Joseph Sowka |
Journal | Optometry (St. Louis, Mo.)
(Optometry)
Vol. 81
Issue 12
Pg. 658-62
(Dec 2010)
ISSN: 1558-1527 [Electronic] United States |
PMID | 21111374
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2010 American Optometric Association. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Emulsions
- Glucocorticoids
- Ophthalmic Solutions
- Fluprednisolone
- difluprednate
|
Topics |
- Administration, Topical
- Black or African American
- Emulsions
- Female
- Fluprednisolone
(adverse effects, analogs & derivatives)
- Glucocorticoids
(adverse effects)
- Humans
- Male
- Middle Aged
- Ocular Hypertension
(chemically induced)
- Ophthalmic Solutions
(adverse effects)
- Scleritis
(drug therapy)
- Uveitis, Anterior
(drug therapy)
|